BOSTON SCIENTIFIC CORPORATION (BSX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 6.43B USD | Liabilities, Current |
| Cash and equivalents | 539.00M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | 3.23B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.43B | $539.00M | (m) | (m) | $3.23B | (m) |
| 2026-03-31 | (m) | $4.57B | $1.45B | (m) | (m) | $3.12B | (m) |
| 2025-12-31 | (m) | $5.44B | $1.97B | (m) | (m) | $2.94B | (m) |
| 2025-09-30 | (m) | $5.33B | $1.27B | (m) | (m) | $2.92B | (m) |
| 2025-06-30 | (m) | $5.19B | $534.00M | (m) | (m) | $2.86B | (m) |
| 2025-03-31 | (m) | $5.06B | $725.00M | (m) | (m) | $2.87B | (m) |
| 2024-12-31 | (m) | $6.40B | $414.00M | (m) | (m) | $2.81B | (m) |
| 2024-09-30 | (m) | $5.91B | $2.50B | (m) | (m) | $2.75B | (m) |
| 2024-06-30 | (m) | $5.58B | $2.91B | (m) | (m) | $2.61B | (m) |
| 2024-03-31 | (m) | $4.92B | $2.33B | (m) | (m) | $2.56B | (m) |
| 2023-12-31 | (m) | $4.93B | $865.00M | (m) | (m) | $2.48B | (m) |
| 2023-09-30 | (m) | $4.58B | $952.00M | (m) | (m) | $2.40B | (m) |
| 2023-06-30 | (m) | $4.56B | $426.00M | (m) | (m) | $2.25B | (m) |
| 2023-03-31 | (m) | $4.08B | $570.00M | (m) | (m) | $2.05B | (m) |
| 2022-12-31 | (m) | $3.80B | $928.00M | (m) | (m) | $1.87B | (m) |
| 2022-09-30 | (m) | $3.55B | $338.00M | (m) | (m) | $1.79B | (m) |
| 2022-06-30 | (m) | $3.88B | $276.00M | (m) | (m) | $1.75B | (m) |
| 2022-03-31 | (m) | $4.28B | $325.00M | (m) | (m) | $1.74B | (m) |
| 2021-12-31 | (m) | $4.27B | $1.93B | (m) | (m) | $1.61B | (m) |
| 2021-09-30 | (m) | $4.02B | $1.95B | (m) | (m) | $1.60B | (m) |
| 2021-06-30 | (m) | $4.07B | $2.67B | (m) | (m) | $1.43B | (m) |
| 2021-03-31 | (m) | $3.39B | $2.02B | (m) | (m) | $1.41B | (m) |
| 2020-12-31 | (m) | $3.68B | $1.73B | (m) | (m) | $1.35B | (m) |
| 2020-09-30 | (m) | $3.30B | $2.02B | (m) | (m) | $1.47B | (m) |
| 2020-06-30 | (m) | $3.11B | $1.72B | (m) | (m) | $1.52B | (m) |
| 2020-03-31 | (m) | $3.98B | $370.00M | (m) | (m) | $1.63B | (m) |
| 2019-12-31 | (m) | $4.87B | $217.00M | (m) | (m) | $1.58B | (m) |
| 2019-09-30 | (m) | $4.25B | $277.00M | (m) | (m) | $1.57B | (m) |
| 2019-06-30 | (m) | $4.85B | $123.00M | (m) | (m) | $1.30B | (m) |
| 2019-03-31 | (m) | $4.48B | $139.00M | (m) | (m) | $1.23B | (m) |
| 2018-12-31 | (m) | $5.26B | $146.00M | (m) | (m) | $1.17B | (m) |
| 2018-09-30 | (m) | $5.08B | $168.00M | (m) | (m) | $1.13B | (m) |
| 2018-06-30 | (m) | $4.75B | $208.00M | (m) | (m) | $1.09B | (m) |
| 2018-03-31 | (m) | $4.99B | $287.00M | (m) | (m) | $1.11B | (m) |
| 2017-12-31 | (m) | $5.65B | $188.00M | (m) | (m) | $1.08B | (m) |
| 2017-09-30 | (m) | $4.83B | $210.00M | (m) | (m) | $1.08B | (m) |
| 2017-06-30 | (m) | $4.30B | $195.00M | (m) | (m) | $1.02B | (m) |
| 2017-03-31 | (m) | $3.49B | $156.00M | (m) | (m) | $971.00M | (m) |
| 2016-12-31 | (m) | $3.59B | $196.00M | (m) | (m) | $955.00M | (m) |
| 2016-09-30 | (m) | $3.02B | $237.00M | (m) | (m) | $998.00M | (m) |
| 2016-06-30 | (m) | $3.18B | $438.00M | (m) | (m) | $981.00M | (m) |
| 2016-03-31 | (m) | $2.61B | $338.00M | (m) | (m) | $1.02B | (m) |
| 2015-12-31 | (m) | $2.43B | $319.00M | (m) | (m) | $1.02B | (m) |
| 2015-09-30 | (m) | $2.24B | $350.00M | (m) | (m) | $1.09B | (m) |
| 2015-06-30 | (m) | $1.94B | $903.00M | (m) | (m) | $968.00M | (m) |
| 2015-03-31 | (m) | $2.46B | $242.00M | (m) | (m) | $958.00M | (m) |
| 2014-12-31 | (m) | $2.85B | $587.00M | (m) | (m) | $946.00M | (m) |
| 2014-09-30 | (m) | $1.82B | $246.00M | (m) | (m) | $989.00M | (m) |
| 2014-06-30 | (m) | $1.77B | $357.00M | (m) | (m) | $949.00M | (m) |
| 2014-03-31 | (m) | $1.72B | $191.00M | (m) | (m) | $926.00M | (m) |
| 2013-12-31 | (m) | $1.82B | $217.00M | (m) | (m) | $897.00M | (m) |
| 2013-09-30 | (m) | $1.90B | $571.00M | (m) | (m) | $895.00M | (m) |
| 2013-06-30 | (m) | $2.48B | $530.00M | (m) | (m) | $842.00M | (m) |
| 2013-03-31 | (m) | $1.64B | $268.00M | (m) | (m) | $851.00M | (m) |
| 2012-12-31 | (m) | $1.77B | $207.00M | (m) | (m) | $884.00M | (m) |
| 2012-09-30 | (m) | $1.81B | $352.00M | (m) | (m) | $911.00M | (m) |
| 2012-06-30 | (m) | $1.79B | $371.00M | (m) | (m) | $898.00M | (m) |
| 2012-03-31 | (m) | $1.67B | $284.00M | (m) | (m) | $889.00M | (m) |
| 2011-12-31 | (m) | $1.81B | $267.00M | (m) | (m) | $931.00M | (m) |
| 2011-09-30 | (m) | $1.89B | $276.00M | (m) | (m) | $972.00M | (m) |
| 2011-06-30 | (m) | $1.89B | $154.00M | (m) | (m) | $927.00M | (m) |
| 2011-03-31 | (m) | $2.04B | $595.00M | (m) | (m) | $899.00M | (m) |
| 2010-12-31 | (m) | $2.61B | $213.00M | (m) | (m) | $894.00M | (m) |
| 2010-09-30 | (m) | $2.96B | $624.00M | (m) | (m) | $923.00M | (m) |
| 2010-06-30 | (m) | $3.72B | $811.00M | (m) | (m) | $885.00M | (m) |
| 2010-03-31 | (m) | $2.91B | $519.00M | (m) | (m) | $906.00M | (m) |
| 2009-12-31 | (m) | $3.02B | $864.00M | (m) | (m) | $920.00M | (m) |
| 2009-09-30 | (m) | $3.18B | $1.38B | (m) | (m) | $942.00M | (m) |
| 2009-06-30 | (m) | $2.75B | $1.19B | (m) | (m) | $878.00M | (m) |
| 2009-03-31 | (m) | (m) | $897.00M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $3.23B | $1.64B | (m) | (m) | $853.00M | (m) |
| 2008-09-30 | (m) | (m) | $1.73B | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $1.62B | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $1.45B | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $1.67B | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |